摘要
目的观察吗替麦考酚酯联合恩替卡韦治疗乙型肝炎病毒相关性肾炎的疗效。方法对10例乙型肝炎相关性肾炎患者,采用吗替麦考酚酯、恩替卡韦联合治疗,疗程为半年。结果9例患者完成随访,其中完全缓解3例(33.3%),部分缓解5例(55.6%),总有效率88.9%,无一例HBV-DNA滴度进行性升高,无明显骨髓抑制、肝肾毒性等不良反应发生。结论吗替麦考酚酯联合恩替卡韦治疗乙型肝炎病毒相关性肾炎是安全有效的。
Objective To observe the clinical curative effect of mycophenolate mofetil combined with entecavir in the treatmerit of patients with hepatitis B virus associated nephritis （ HBV - GN）. Methods Ten patients with HBV - GN were treated with leflunomide medium amount combined with entecavir, and were observed 6 months. Results Nine out of ten cases finished the study, Six cases completely relieved（33.3% ） , 5 cases partly relieved（55.6% ）, and the effective rate was 88.9%. There was no obvious hepatoxicity, bone marrow depression and so on untoward reactions, Conclusion This preliminary study demonstrated that the combined therapy with nay - cophonolate mofetil and entecavir is effective and safe for patients with HBV - GN.
出处
《临床医学》
CAS
2008年第8期32-33,共2页
Clinical Medicine
